Importantly, all these effects were obtained with negligible amounts of antibody released in the circulation and without any sign of discomfort in treated mice, minimizing the risk of toxicity without compromising the adjuvant and the anti-tumor effects of anti-CTLA-4. The gene discussed is CTLA4; the disease is neoplasm.